SI2503338T1 - CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij - Google Patents

CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij

Info

Publication number
SI2503338T1
SI2503338T1 SI200831377T SI200831377T SI2503338T1 SI 2503338 T1 SI2503338 T1 SI 2503338T1 SI 200831377 T SI200831377 T SI 200831377T SI 200831377 T SI200831377 T SI 200831377T SI 2503338 T1 SI2503338 T1 SI 2503338T1
Authority
SI
Slovenia
Prior art keywords
biomarker
therapies
assessing
efficacy
diseases
Prior art date
Application number
SI200831377T
Other languages
English (en)
Slovenian (sl)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of SI2503338T1 publication Critical patent/SI2503338T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI200831377T 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij SI2503338T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP12002502.8A EP2503338B1 (en) 2007-10-24 2008-10-15 CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
SI2503338T1 true SI2503338T1 (sl) 2015-06-30

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831377T SI2503338T1 (sl) 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Country Status (14)

Country Link
US (1) US20100209942A1 (cg-RX-API-DMAC7.html)
EP (2) EP2503338B1 (cg-RX-API-DMAC7.html)
JP (2) JP4982610B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160029869A (cg-RX-API-DMAC7.html)
CA (1) CA2702635A1 (cg-RX-API-DMAC7.html)
CY (2) CY1113403T1 (cg-RX-API-DMAC7.html)
DK (2) DK2201376T3 (cg-RX-API-DMAC7.html)
ES (2) ES2532361T3 (cg-RX-API-DMAC7.html)
FI (1) FI20070795A0 (cg-RX-API-DMAC7.html)
HR (2) HRP20120743T1 (cg-RX-API-DMAC7.html)
PL (2) PL2503338T3 (cg-RX-API-DMAC7.html)
PT (2) PT2201376E (cg-RX-API-DMAC7.html)
SI (2) SI2503338T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201400710A1 (ru) 2008-01-18 2015-03-31 Президент Энд Феллоуз Оф Гарвард Колледж Способы детекции признаков заболеваний или состояний в жидкостях организма
CN103124795A (zh) 2010-07-23 2013-05-29 哈佛大学校长及研究员协会 利用吞噬细胞检测疾病或病症的方法
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
US20130210647A1 (en) 2010-07-23 2013-08-15 President And Fellows Of Harvard College Methods of Detecting Cardiovascular Diseases or Conditions
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20140179805A1 (en) 2012-06-15 2014-06-26 Harry Stylli Methods of detecting diseases or conditions
US20150141260A1 (en) 2012-06-15 2015-05-21 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
ES2683854T3 (es) * 2013-02-14 2018-09-28 Faron Pharmaceuticals Oy Un método para determinar biomarcadores relacionados con el síndrome de distrés respiratorio agudo (ARDS), un método para monitorizar el desarrollo y tratamiento de ARDS en un paciente
HK1220253A1 (zh) 2013-03-09 2017-04-28 Harry Stylli 诊断前列腺癌症的方法
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
EP3693742B1 (en) 2014-09-11 2022-04-06 Harry Stylli Methods of detecting prostate cancer
EA038349B1 (ru) 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
WO2002077174A2 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
DE602004027797D1 (de) * 2003-03-28 2010-08-05 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73
US7772192B2 (en) * 2003-06-03 2010-08-10 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
JP2009543862A (ja) * 2006-07-14 2009-12-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ガンのバイオマーカーおよびその使用方法

Also Published As

Publication number Publication date
SI2201376T1 (sl) 2012-09-28
JP2012159514A (ja) 2012-08-23
CY1113403T1 (el) 2016-06-22
PL2503338T3 (pl) 2015-06-30
WO2009053523A1 (en) 2009-04-30
DK2201376T3 (da) 2012-10-15
US20100209942A1 (en) 2010-08-19
KR20160029869A (ko) 2016-03-15
JP2011501176A (ja) 2011-01-06
PT2503338E (pt) 2015-03-05
KR20100059902A (ko) 2010-06-04
PL2201376T3 (pl) 2013-01-31
EP2503338B1 (en) 2014-12-24
DK2503338T3 (en) 2015-03-09
JP4982610B2 (ja) 2012-07-25
PT2201376E (pt) 2012-08-20
HRP20120743T1 (hr) 2012-10-31
ES2532361T3 (es) 2015-03-26
EP2201376A4 (en) 2011-03-23
JP5619810B2 (ja) 2014-11-05
EP2503338A2 (en) 2012-09-26
EP2503338A3 (en) 2013-03-13
EP2201376B1 (en) 2012-08-08
EP2201376A1 (en) 2010-06-30
ES2389751T3 (es) 2012-10-31
CY1116089T1 (el) 2017-02-08
CA2702635A1 (en) 2009-04-30
HRP20150181T1 (hr) 2015-06-19
FI20070795A0 (fi) 2007-10-24

Similar Documents

Publication Publication Date Title
HRP20150181T1 (hr) Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
ZA201108907B (en) New biomarkers for assessing kidney diseases
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
GB0608829D0 (en) In-situ measurement of physical parameters
GB0717637D0 (en) Future cardiac event biomarkers
GB2450351B (en) Monitoring an Immunoassay
IL206631A0 (en) Biomarkers for the prediction of renal injury
IL217725A0 (en) Means and methods for diagnosing thyroid disorders
EP2260107A4 (en) TESTS FOR THE DIAGNOSIS AND ASSESSMENT OF TREATMENT OPTIONS FOR MORBUS POMPE
TWI351185B (en) Methods for interference measurement and prediction
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS
GB0712407D0 (en) Authorised debugging
EP1973351A4 (en) MONITOR
GB0704515D0 (en) Diagnosing psychotic disorders
AU2009900444A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0606920D0 (en) Biomarker for schizophrenic disorders
PL382585A1 (pl) Sposób realizowania transakcji handlowych
PL381454A1 (pl) Sposób diagnozowania stanu technicznego obiektów mostowych
AU2008902580A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0720545D0 (en) Diagnosing physchotic disorders
GB0622351D0 (en) Non-invasive monitoring
PL381670A1 (pl) Sposób monitorowania elementów konstrukcji
GB0811751D0 (en) Portable device for measuring the physical symptoms of disease
AU2009902698A0 (en) Agents and methods for diagnosing a condition